Hybio Pharmaceutical Co., Ltd.
300199
Rang in aandelen
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Aandeelprijs
$3.69
Marktkapitalisatie
$3.11B
Verandering (1 dag)
-7.75%
Verandering (1 jaar)
21.56%
Land
CN
Handel Hybio Pharmaceutical Co., Ltd. (300199)
Categorie
Healthcare
Aantal uitstaande aandelen voor Hybio Pharmaceutical Co., Ltd. (300199)
Aantal uitstaande aandelen per June 2026: 883.24M
Volgens de laatste financiële rapporten en de aandelenkoers van Hybio Pharmaceutical Co., Ltd. bedraagt het huidige aantal uitstaande aandelen 883.24M. Aan het einde van December 2024 had het bedrijf 868.27M uitstaande aandelen. Het aantal uitstaande aandelen wordt meestal beïnvloed door aandelensplitsingen en terugkoop van aandelen.
Geschiedenis van uitstaande aandelen van Hybio Pharmaceutical Co., Ltd. (300199) van 2007 tot 2026
Uitstaande aandelen aan het einde van elk jaar
| Jaar | Uitstaande aandelen | Wijzigen |
|---|---|---|
| 2026 (TTM) | 883.24M | -3.39% |
| 2025 | 914.25M | 5.30% |
| 2024 | 868.27M | -2.00% |
| 2023 | 885.99M | 0.31% |
| 2022 | 883.24M | 0.00% |
| 2021 | 883.24M | 0.00% |
| 2020 | 883.24M | 0.00% |
| 2019 | 883.24M | -3.74% |
| 2018 | 917.60M | 0.19% |
| 2017 | 915.89M | 3.54% |
| 2016 | 884.62M | -1.50% |
| 2015 | 898.06M | -0.54% |
| 2014 | 902.96M | 11.19% |
| 2013 | 812.07M | -0.53% |
| 2012 | 816.35M | 9.05% |
| 2011 | 748.60M | 23.95% |
| 2010 | 603.97M | 2.47% |
| 2009 | 589.43M | 26.14% |
| 2008 | 467.27M | 0.00% |
| 2007 | 467.27M | 0.00% |
Uitstaande aandelen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Uitstaande aandelen | Verschil | Land |
|---|---|---|---|
| 434.78M | -50.77% |
DE
|
|
| 434.78M | -50.77% |
DE
|
|
| 1.56B | 76.91% |
JP
|
|
| 233.66M | -73.55% |
CH
|
|
| 2.40B | 171.65% |
IN
|
